Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RNAZ
DateTimeSourceHeadlineSymbolCompany
18/06/202421:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAZTransCode Therapeutics Inc
18/06/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAZTransCode Therapeutics Inc
14/06/202413:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
13/06/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
10/06/202413:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
10/06/202412:00GlobeNewswire Inc.Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsNASDAQ:RNAZTransCode Therapeutics Inc
07/06/202421:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
07/06/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
29/05/202414:15GlobeNewswire Inc.TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
20/05/202421:00Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:RNAZTransCode Therapeutics Inc
15/05/202422:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
13/05/202422:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
13/05/202413:30GlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
10/05/202421:50Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
10/05/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
15/04/202414:00GlobeNewswire Inc.TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsNASDAQ:RNAZTransCode Therapeutics Inc
03/04/202414:10GlobeNewswire Inc.TransCode Therapeutics Reports 2023 Results; Provides Business UpdateNASDAQ:RNAZTransCode Therapeutics Inc
28/03/202412:30GlobeNewswire Inc.TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerNASDAQ:RNAZTransCode Therapeutics Inc
11/03/202413:00GlobeNewswire Inc.TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentNASDAQ:RNAZTransCode Therapeutics Inc
06/03/202421:15GlobeNewswire Inc.TransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressNASDAQ:RNAZTransCode Therapeutics Inc
20/02/202413:00GlobeNewswire Inc.TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticNASDAQ:RNAZTransCode Therapeutics Inc
15/02/202421:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
14/02/202401:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
31/01/202421:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
31/01/202421:05GlobeNewswire Inc.Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketNASDAQ:RNAZTransCode Therapeutics Inc
29/01/202413:30GlobeNewswire Inc.TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerNASDAQ:RNAZTransCode Therapeutics Inc
22/01/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
22/01/202421:45GlobeNewswire Inc.TransCode Therapeutics Announces Closing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
20/01/202402:57Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:RNAZTransCode Therapeutics Inc
19/01/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNAZTransCode Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RNAZ

Your Recent History

Delayed Upgrade Clock